T
50
2
TGT
53
3
GIS
46
3
MET
51
4
FITB
73
3
SNA
52
2
GOOG
51
9
TRV
52
4
SYF
37
5
JNJ
75
-2
MTB
69
2
RCL
62
7
MRK
55
2
MNST
65
3
LB
70
2
MCD
54
2
BLK
58
4
URI
53
4
ACN
13
2
FDX
77
2
T
50
2
TGT
53
3
GIS
46
3
MET
51
4
FITB
73
3
SNA
52
2
GOOG
51
9
TRV
52
4
SYF
37
5
JNJ
75
-2
MTB
69
2
RCL
62
7
MRK
55
2
MNST
65
3
LB
70
2
MCD
54
2
BLK
58
4
URI
53
4
ACN
13
2
FDX
77
2
Financhill
Back

Cosmo Pharmaceuticals NV 10K Form

Buy
81

CMOPF
Cosmo Pharmaceuticals NV

Last Price:
$158.04
Seasonality Move:
11.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CMOPF News And Ratings

See the #1 stock for the next 7 days that we like better than CMOPF

CMOPF Financial Statistics

Sales & Book Value

Annual Sales: $288.6M
Cash Flow: $0
Price / Cash Flow: 35.29
Annual Sales: $33.30
Price / Book: 2.32

Profitability

EPS (TTM): 3.57210
Net Income (TTM): $59.6M
Gross Margin: $237.5M
Return on Equity: 15.06%
Return on Assets: 10.72%

Cosmo Pharmaceuticals NV Earnings Forecast

Key Cosmo Pharmaceuticals NV Financial Ratios

  • The Gross Profit Margin over the past 21 years for CMOPF is 82.29%.
  • The Selling, General & Administrative Expenses for CMOPF have been equal to 13.60% of Gross Profit Margin.
  • The Research & Development expenses have been 14.26% of Revenue.
  • The Interest Expense is 0.09% of Operating Income.
  • The Net Earning history of CMOPF is 49.92% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 12 years.

Cosmo Pharmaceuticals NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CMOPF
Website: cosmopharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.85
Quick Ratio: 4.48

Price-to-Earnings

Trailing P/E Ratio: 18
Forward P/E Ratio: 0

CMOPF Technical Analysis vs Fundamental Analysis

Buy
81
Cosmo Pharmaceuticals NV (CMOPF) is a Buy

Is Cosmo Pharmaceuticals NV a Buy or a Sell?